Back to Search
REHAM GAAFAR, MD
MD
Family Medicine Physician
NPI: 1760126130IndividualAccepts Medicare
Specialties, Licenses & Credentials
CMS Specialties
PrimaryFAMILY PRACTICE
Education
OTHER
Class of 2021
Research & Publications (19)
A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
PMID 19502050·Eur J Cancer·2009
8-other
Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma.
PMID 18640302·Ann Thorac Surg·2008
8-other
Evaluation of simian virus-40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma.
PMID 17610473·Pathol Int·2007
8-other
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
PMID 18089874·J Clin Oncol·2007
3-trial
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975.
PMID 16968876·Ann Oncol·2006
2-rct
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
PMID 16446322·J Clin Oncol·2006
3-trial
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
PMID 16549997·Anticancer Drugs·2006
3-trial
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
PMID 16192580·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 6540 WINTON RD
CINCINNATI, OH 45224 - Phone
- (513) 981-4180
Quick Facts
- NPI
- 1760126130
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 5
- Publications
- 19
Are you this provider?
Claim Your Profile